
    
      BMS-936558 will be administered as an i.v. infusion, using a volumetric pump with a 0.2
      micron in-line filter at the protocol-specified dose(s) and rate.

      The vaccine consists of the following peptides: gp100280-288 (288V), and NY-ESO-1157-165
      (165V).

      NOTE: *Patients in cohorts 1-5 will receive the peptide vaccine, but not those in cohort 6.

      Blood samples are collected for pharmacokinetic and immunologic analysis.

      After completion of study therapy, patients are followed up periodically for 2 years.
    
  